Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$825.86 +4.82 (+0.59%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$826.28 +0.41 (+0.05%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $720, reflecting strong market interest and potential for growth.
  • Recent insider purchases indicate confidence in the company's future, with executives acquiring shares at significant values.
  • Analysts have upgraded their ratings on Eli Lilly and Co, with many recommending a "buy" due to positive earnings forecasts.

Cons of Eli Lilly and Company

  • Despite recent upgrades, some analysts have issued "hold" ratings, indicating caution about the stock's short-term performance.
  • The stock has seen fluctuations, which may indicate volatility and risk for investors looking for stable returns.
  • Insider ownership is relatively low at 0.14%, which may suggest less alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$777.08 billion
P/E Ratio
53.98
Consensus Rating
Moderate Buy
Consensus Price Target
$938.61 (+13.7% Upside)
Volume
2.21 million shares
Average Volume
3.51 million shares
Today's Range
$812.50
$834.15
50-Day Range
$696.08
$854.40
52-Week Range
$623.78
$935.63
Dividend Yield
0.73%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$190.38 -2.09 (-1.08%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$190.48 +0.09 (+0.05%)
As of 10/24/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $191.93, reflecting a strong market position and potential for growth.
  • Johnson & Johnson has a solid market capitalization of approximately $462.23 billion, indicating stability and investor confidence.
  • Recent analyst upgrades have increased price targets, with some analysts setting targets as high as $215.00, suggesting strong future performance.

Cons of Johnson & Johnson

  • Insider ownership is relatively low at 0.16%, which may raise concerns about alignment between management and shareholder interests.
  • The company's debt-to-equity ratio is 0.50, indicating a moderate level of debt that could impact financial flexibility.
  • Despite recent upgrades, some analysts have assigned a "Hold" rating, suggesting caution among certain market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$463.72 billion
P/E Ratio
18.38
Consensus Rating
Moderate Buy
Consensus Price Target
$199.05 (+4.6% Upside)
Volume
6.90 million shares
Average Volume
8.76 million shares
Today's Range
$189.42
$192.31
50-Day Range
$174.22
$193.78
52-Week Range
$140.68
$194.48
Dividend Yield
2.70%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$228.06 -0.19 (-0.08%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$228.14 +0.08 (+0.03%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received multiple analyst upgrades recently, with target prices raised significantly, indicating strong market confidence in the company's future performance.
  • The current stock price is around $232, reflecting a positive trend and potential for growth as analysts have set high target prices, some exceeding $250.
  • AbbVie has a robust market capitalization of approximately $410 billion, suggesting stability and a strong position in the pharmaceutical industry.

Cons of AbbVie

  • Insider ownership is relatively low, with only 0.08% of the stock held by insiders, which may raise concerns about alignment between management and shareholder interests.
  • The company's high P/E ratio of 110.51 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • AbbVie has a high debt-to-equity ratio of 44.14, indicating that the company relies significantly on debt financing, which can be risky in volatile market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$403.22 billion
P/E Ratio
108.60
Consensus Rating
Moderate Buy
Consensus Price Target
$234.80 (+3.0% Upside)
Volume
3.55 million shares
Average Volume
6.22 million shares
Today's Range
$226.25
$229.04
50-Day Range
$205.99
$244.77
52-Week Range
$163.81
$244.81
Dividend Yield
2.87%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$362.78 +2.33 (+0.65%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$363.70 +0.92 (+0.25%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company has demonstrated strong revenue growth, with a recent quarterly revenue increase of approximately 12.9% compared to the same period last year.
  • UnitedHealth Group has a solid return on equity of over 23%, indicating effective management and profitability relative to shareholder equity.
  • The current stock price is around $385, which reflects a favorable valuation in light of the company's growth prospects and market position.

Cons of UnitedHealth Group

  • The company recently missed earnings expectations, reporting earnings per share of $4.08, which was below the consensus estimate of $4.45, raising concerns about future performance.
  • UnitedHealth Group's net margin is relatively modest at around 5.04%, which may indicate challenges in maintaining profitability amidst rising costs in the healthcare sector.
  • There is a significant level of competition in the healthcare industry, which could impact UnitedHealth Group's market share and pricing power.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$326.45 billion
P/E Ratio
15.72
Consensus Rating
Moderate Buy
Consensus Price Target
$385.13 (+6.2% Upside)
Volume
5.45 million shares
Average Volume
7.84 million shares
Today's Range
$360.03
$365.42
50-Day Range
$299.83
$369.88
52-Week Range
$234.60
$630.73
Dividend Yield
2.45%
Novartis stock logo

5. Novartis NYSE:NVS

$130.48 -1.16 (-0.88%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$129.98 -0.51 (-0.39%)
As of 10/24/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $131, reflecting a strong market position and investor confidence.
  • Recent upgrades from analysts, including a "strong-buy" rating, indicate positive sentiment and potential for price appreciation.
  • Novartis AG reported a significant year-over-year revenue increase of over 12%, showcasing robust business growth.

Cons of Novartis

  • Despite recent growth, the stock has faced volatility, with a beta of 0.64 indicating lower risk but also potential for slower price movements.
  • Analysts have issued several "hold" ratings, suggesting that while the stock is stable, there may be limited upside in the short term.
  • Three analysts have rated the stock as a "sell," indicating concerns about future performance and market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$278.08 billion
P/E Ratio
18.99
Consensus Rating
Hold
Consensus Price Target
$120.33 (-7.8% Downside)
Volume
1.22 million shares
Average Volume
1.63 million shares
Today's Range
$130.28
$131.54
50-Day Range
$122.34
$132.41
52-Week Range
$96.06
$133.55
Dividend Yield
1.98%
AstraZeneca stock logo

6. AstraZeneca NASDAQ:AZN

$83.29 -0.11 (-0.13%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$83.12 -0.17 (-0.20%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $84.69, which is near its twelve-month high, indicating strong market performance.
  • AstraZeneca has a consensus rating of "Moderate Buy" from analysts, suggesting positive sentiment towards the stock.
  • The company reported a revenue increase of 16.1% compared to the same quarter last year, showcasing robust growth.

Cons of AstraZeneca

  • Deutsche Bank downgraded AstraZeneca from a "hold" to a "sell" rating, which may indicate potential concerns about future performance.
  • The company recently cut its dividend, which could signal financial strain or a shift in strategy that may not favor shareholders.
  • AstraZeneca has a current ratio of 0.86, suggesting potential liquidity issues, as it may not have enough short-term assets to cover its liabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$258.66 billion
P/E Ratio
31.31
Consensus Rating
Moderate Buy
Consensus Price Target
$86.00 (+3.3% Upside)
Volume
2.38 million shares
Average Volume
6.12 million shares
Today's Range
$82.92
$83.52
50-Day Range
$73.53
$85.87
52-Week Range
$61.24
$86.57
Dividend Yield
1.21%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$53.02 -0.21 (-0.39%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$53.09 +0.07 (+0.13%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $55, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Recent earnings reports show that Novo Nordisk has consistently exceeded earnings expectations, indicating strong financial performance and effective management.
  • The company has a high return on equity, suggesting efficient use of shareholders' equity to generate profits, which is attractive to investors.

Cons of Novo Nordisk A/S

  • The company has recently cut its dividend, which may signal potential cash flow issues or a shift in financial strategy that could concern income-focused investors.
  • Despite strong earnings, the revenue reported was below analysts' expectations, which could indicate challenges in meeting future growth targets.
  • Market volatility and economic uncertainties could impact the stock price, making it a riskier investment in the current climate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$237.67 billion
P/E Ratio
14.57
Consensus Rating
Moderate Buy
Consensus Price Target
$76.00 (+43.3% Upside)
Volume
8.46 million shares
Average Volume
12.67 million shares
Today's Range
$52.93
$53.55
50-Day Range
$53.02
$61.86
52-Week Range
$45.05
$114.19
Dividend Yield
1.55%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$126.78 +0.44 (+0.35%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$126.98 +0.20 (+0.16%)
As of 10/24/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $132, which reflects a stable position in the market.
  • Abbott Laboratories reported a strong quarterly earnings performance, meeting consensus estimates with earnings per share of $1.30, indicating solid profitability.
  • The company has a robust net margin of approximately 31.88%, suggesting effective cost management and strong profitability relative to its revenue.

Cons of Abbott Laboratories

  • The company’s revenue for the latest quarter fell slightly short of analysts' expectations, which may raise concerns about future growth potential.
  • Abbott Laboratories has a P/E ratio of around 15.94, which, while reasonable, may suggest that the stock is not undervalued compared to its peers.
  • Insider trading activity, such as the recent sale of shares by the CFO, could indicate a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$219.89 billion
P/E Ratio
15.89
Consensus Rating
Moderate Buy
Consensus Price Target
$147.00 (+15.9% Upside)
Volume
5.07 million shares
Average Volume
6.62 million shares
Today's Range
$125.00
$128.11
50-Day Range
$126.44
$136.82
52-Week Range
$110.86
$141.23
Dividend Yield
1.87%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$87.54 +0.36 (+0.41%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$87.72 +0.18 (+0.21%)
As of 10/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck recently reported strong earnings, with earnings per share exceeding analysts' expectations, indicating robust financial performance.
  • The current stock price is around $87.61, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Merck has a solid dividend yield of approximately 3.8%, providing a steady income stream for investors.

Cons of Merck & Co., Inc.

  • Recent analyst reports have downgraded Merck's stock rating, with several firms reducing their price targets, which may signal caution among investors.
  • The company’s revenue for the last quarter fell short of analyst estimates, which could indicate potential challenges in meeting future growth expectations.
  • Merck's debt-to-equity ratio is 0.69, which, while manageable, suggests that the company has a moderate level of debt that could impact financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$217.76 billion
P/E Ratio
13.49
Consensus Rating
Hold
Consensus Price Target
$104.33 (+19.2% Upside)
Volume
7.90 million shares
Average Volume
12.27 million shares
Today's Range
$87.11
$88.06
50-Day Range
$77.70
$90.13
52-Week Range
$73.31
$106.49
Dividend Yield
3.70%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$573.07 +1.16 (+0.20%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$568.75 -4.32 (-0.75%)
As of 10/24/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $500, which is significantly lower than its fifty-two week high of $610.97, potentially offering a buying opportunity for investors.
  • The company reported strong quarterly earnings, with earnings per share of $5.79, exceeding analysts' expectations, indicating robust financial performance.
  • Thermo Fisher Scientific Inc. has a solid market capitalization of approximately $214.64 billion, reflecting its strong position in the market and investor confidence.

Cons of Thermo Fisher Scientific

  • The P/E ratio of 32.88 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent insider selling, including significant transactions by the CEO and CAO, may raise concerns about the company's future prospects and insider confidence.
  • The company's beta of 0.77 indicates lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$215.96 billion
P/E Ratio
33.11
Consensus Rating
Moderate Buy
Consensus Price Target
$595.75 (+4.0% Upside)
Volume
1.66 million shares
Average Volume
2.57 million shares
Today's Range
$569.79
$575.82
50-Day Range
$459.34
$573.07
52-Week Range
$385.46
$610.97
Dividend Yield
0.30%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$546.51 -4.79 (-0.87%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$545.00 -1.51 (-0.28%)
As of 10/24/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Recent analyst ratings have been largely positive, with multiple firms setting target prices above the current stock price, indicating potential for growth.
  • The current stock price is around $541, which is significantly higher than its 1-year low of $425, suggesting a recovery and upward trend in value.
  • Intuitive Surgical, Inc. has a strong market capitalization of approximately $194 billion, reflecting its substantial presence and stability in the medical equipment sector.

Cons of Intuitive Surgical

  • The stock has a relatively high P/E ratio, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Insider selling has been noted, with significant shares sold recently, which could signal a lack of confidence from those within the company.
  • Despite positive ratings, one analyst has issued a Sell rating, suggesting that not all market experts are optimistic about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$197.63 billion
P/E Ratio
72.29
Consensus Rating
Moderate Buy
Consensus Price Target
$602.32 (+10.2% Upside)
Volume
2.69 million shares
Average Volume
2.74 million shares
Today's Range
$541.46
$552.45
50-Day Range
$429.59
$551.30
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$291.76 -1.13 (-0.39%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$292.02 +0.25 (+0.09%)
As of 10/24/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has received multiple upgrades from analysts, including a recent upgrade to a "buy" rating, indicating positive sentiment and potential for stock price appreciation.
  • The stock price is currently around $292, which may present a buying opportunity for investors looking for value in the biotech sector.
  • Several analysts have raised their price targets for Amgen Inc., suggesting confidence in the company's future performance and growth potential.

Cons of Amgen

  • Despite recent upgrades, the stock has shown some volatility, with a recent trading session reflecting a slight decline, which may concern risk-averse investors.
  • Amgen Inc. has received an "underperform" rating from some analysts, indicating that there may be better investment opportunities available in the market.
  • The company's debt-to-equity ratio is relatively high, which could indicate potential financial risk and may deter conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.68 billion
P/E Ratio
23.86
Consensus Rating
Hold
Consensus Price Target
$300.94 (+3.1% Upside)
Volume
1.38 million shares
Average Volume
2.17 million shares
Today's Range
$290.66
$293.94
50-Day Range
$271.18
$303.33
52-Week Range
$253.30
$335.88
Dividend Yield
3.22%
Danaher stock logo

13. Danaher NYSE:DHR

$223.03 +0.30 (+0.14%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$224.52 +1.49 (+0.67%)
As of 10/24/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. has recently received a price target increase to $250, indicating a potential upside from its current stock price, which is around $218. This suggests that analysts are optimistic about the company's future performance.
  • The company reported a strong earnings per share (EPS) of $1.89, surpassing expectations, which reflects its solid financial health and operational efficiency.
  • Danaher Co. has a robust market capitalization of approximately $156.12 billion, showcasing its significant presence and stability in the market.

Cons of Danaher

  • The current price-to-earnings (P/E) ratio of 46.39 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Danaher Co. has a relatively high PEG ratio of 3.01, indicating that its stock price may be high relative to its expected earnings growth, which could signal potential overvaluation.
  • Recent trading volumes have been significantly lower than average, which may indicate reduced investor interest or liquidity issues in the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.33 billion
P/E Ratio
45.99
Consensus Rating
Moderate Buy
Consensus Price Target
$243.39 (+9.1% Upside)
Volume
3.96 million shares
Average Volume
5.04 million shares
Today's Range
$222.18
$225.05
50-Day Range
$181.56
$223.03
52-Week Range
$171.00
$258.23
Dividend Yield
0.59%
Boston Scientific stock logo

14. Boston Scientific NYSE:BSX

$101.08 -1.31 (-1.28%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$101.10 +0.02 (+0.02%)
As of 10/24/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Recent analyst ratings have been overwhelmingly positive, with multiple firms reiterating "buy" ratings and setting price targets that suggest significant upside potential from the current stock price.
  • The current stock price is around $98.44, which is considered attractive given the company's strong market position and growth prospects in the medical equipment sector.
  • Boston Scientific Co. has a solid market capitalization of approximately $146 billion, indicating a strong presence in the industry and the ability to invest in future growth opportunities.

Cons of Boston Scientific

  • The stock has experienced fluctuations, with a one-year high of $109.50 and a low of $80.64, indicating potential volatility that could affect short-term investors.
  • Despite positive ratings, the price-to-earnings ratio is relatively high, which may suggest that the stock is overvalued compared to its earnings, posing a risk for new investors.
  • Insider selling activity has been noted, with significant shares sold recently, which could signal a lack of confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.72 billion
P/E Ratio
54.06
Consensus Rating
Buy
Consensus Price Target
$123.77 (+22.4% Upside)
Volume
6.80 million shares
Average Volume
10.08 million shares
Today's Range
$101.03
$102.99
50-Day Range
$94.92
$108.15
52-Week Range
$80.64
$109.50
Dividend Yield
N/A
Gilead Sciences stock logo

15. Gilead Sciences NASDAQ:GILD

$120.94 +0.20 (+0.17%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$120.99 +0.05 (+0.04%)
As of 10/24/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $121.30, which reflects a positive outlook and potential for growth based on recent analyst upgrades.
  • Analysts at TD Cowen recently raised their price target for Gilead Sciences, Inc. from $115.00 to $125.00, indicating confidence in the company's future performance.
  • Gilead Sciences, Inc. has a strong market capitalization of approximately $150.51 billion, suggesting stability and a solid position in the biopharmaceutical sector.

Cons of Gilead Sciences

  • Insider sales have occurred recently, with executives selling a significant number of shares, which may raise concerns about their confidence in the company's short-term performance.
  • The company has a debt-to-equity ratio of 1.13, indicating that it has a relatively high level of debt compared to its equity, which could pose risks in a volatile market.
  • Despite recent upgrades, some analysts maintain a "neutral" rating, suggesting that there may be limitations to the stock's upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$149.82 billion
P/E Ratio
24.09
Consensus Rating
Moderate Buy
Consensus Price Target
$122.61 (+1.4% Upside)
Volume
5.44 million shares
Average Volume
7.70 million shares
Today's Range
$118.71
$121.15
50-Day Range
$110.56
$124.08
52-Week Range
$86.08
$124.61
Dividend Yield
2.60%
Stryker stock logo

16. Stryker NYSE:SYK

$381.86 -1.20 (-0.31%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$382.31 +0.45 (+0.12%)
As of 10/24/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $374, which may present a buying opportunity for investors looking for growth in the medical technology sector.
  • Fifteen analysts have rated Stryker Co. with a Buy rating, indicating strong confidence in the company's future performance.
  • Recent upgrades from analysts, including a target price increase from Wells Fargo to $445, suggest positive market sentiment and potential for stock appreciation.

Cons of Stryker

  • The stock has a relatively high price-to-earnings ratio of 49.63, which may indicate that it is overvalued compared to its earnings potential.
  • Recent insider selling, including a significant transaction by a director, could signal a lack of confidence in the company's short-term prospects.
  • Despite positive ratings, some analysts have issued hold ratings, suggesting caution and a lack of consensus on the stock's immediate growth potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.45 billion
P/E Ratio
50.58
Consensus Rating
Moderate Buy
Consensus Price Target
$432.24 (+13.2% Upside)
Volume
1.14 million shares
Average Volume
1.49 million shares
Today's Range
$379.21
$384.81
50-Day Range
$364.07
$394.67
52-Week Range
$329.16
$406.19
Dividend Yield
0.87%
Pfizer stock logo

17. Pfizer NYSE:PFE

$24.78 +0.12 (+0.47%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$24.78 0.00 (0.00%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The company recently reported a revenue increase of over 10% year-over-year, indicating strong growth and demand for its products.
  • Pfizer Inc. has set its earnings per share (EPS) guidance for FY 2025 between 2.900 and 3.100, suggesting potential for profitability and positive financial performance.
  • The current stock price is around $28, which is considered reasonable given the company's strong market position and product pipeline.

Cons of Pfizer

  • The payout ratio is currently high at 91.49%, which may raise concerns about the sustainability of the dividend in the long term.
  • Analysts have mixed ratings on the stock, with a significant number issuing "Hold" ratings, indicating uncertainty about future performance.
  • Recent price targets from analysts suggest limited upside potential, with many setting targets around $28, which may not provide significant returns for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.26 billion
P/E Ratio
13.18
Consensus Rating
Hold
Consensus Price Target
$28.13 (+13.5% Upside)
Volume
27.40 million shares
Average Volume
58.97 million shares
Today's Range
$24.68
$24.83
50-Day Range
$23.61
$27.37
52-Week Range
$20.92
$29.17
Dividend Yield
6.97%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$51.64 +2.12 (+4.28%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$51.30 -0.34 (-0.66%)
As of 10/24/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple upgrades from analysts, including a recent upgrade to an "overweight" rating, indicating strong confidence in the stock's potential for growth.
  • The current stock price is around $50, which is below the consensus price target of $62.67, suggesting potential for price appreciation.
  • Sanofi reported a significant revenue of $11.34 billion in its latest quarterly earnings, exceeding analysts' expectations, which reflects strong operational performance.

Cons of Sanofi

  • Sanofi's earnings per share for the latest quarter missed analysts' consensus estimates, which may raise concerns about its short-term profitability.
  • The company's revenue decreased by 7.0% compared to the same quarter last year, indicating potential challenges in maintaining growth momentum.
  • Despite positive analyst ratings, the stock has shown volatility, which could pose risks for investors seeking stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$121.60 billion
P/E Ratio
12.41
Consensus Rating
Buy
Consensus Price Target
$62.67 (+21.4% Upside)
Volume
4.64 million shares
Average Volume
3.77 million shares
Today's Range
$51.25
$52.20
50-Day Range
$45.07
$51.64
52-Week Range
$44.62
$60.12
Dividend Yield
3.23%
Medtronic stock logo

19. Medtronic NYSE:MDT

$93.76 -0.46 (-0.48%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$93.68 -0.08 (-0.09%)
As of 10/24/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $95.97, which reflects a stable market position and potential for growth.
  • Medtronic plc has a strong dividend payout ratio of 78.24%, indicating a commitment to returning value to shareholders.
  • Recent analyst ratings show a consensus of "Moderate Buy," with multiple brokerages raising their price targets, suggesting positive market sentiment.

Cons of Medtronic

  • Some analysts have issued a "Sell" rating, indicating concerns about the stock's future performance.
  • The company has experienced fluctuations in price targets, with some brokerages reducing their expectations, which may indicate uncertainty.
  • Insider selling activity, such as the recent sale by an executive vice president, could raise red flags about the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$120.84 billion
P/E Ratio
25.83
Consensus Rating
Moderate Buy
Consensus Price Target
$102.82 (+9.7% Upside)
Volume
4.31 million shares
Average Volume
6.51 million shares
Today's Range
$93.29
$94.96
50-Day Range
$89.92
$98.46
52-Week Range
$79.29
$99.37
Dividend Yield
3.01%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$421.39 -1.24 (-0.29%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$421.22 -0.16 (-0.04%)
As of 10/24/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company recently reported earnings per share of $4.52, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • Vertex Pharmaceuticals Incorporated has a robust net margin of approximately 31.86%, suggesting efficient management and profitability, which can be attractive to investors looking for stable returns.
  • With a return on equity of about 23.91%, the company demonstrates effective use of shareholder equity to generate profits, a key indicator of financial health.

Cons of Vertex Pharmaceuticals

  • Despite recent successes, the company has faced significant fluctuations in earnings, including a loss of ($12.83) EPS during the same quarter last year, which raises concerns about consistency in profitability.
  • Analysts have varied opinions on the stock, with some recent price target reductions indicating uncertainty about future performance, which could lead to volatility in the stock price.
  • Insider ownership is relatively low at 0.20%, which may suggest a lack of confidence from those closest to the company regarding its future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$108.36 billion
P/E Ratio
30.12
Consensus Rating
Moderate Buy
Consensus Price Target
$494.38 (+17.3% Upside)
Volume
1.00 million shares
Average Volume
1.45 million shares
Today's Range
$420.60
$425.86
50-Day Range
$376.62
$426.44
52-Week Range
$362.50
$519.88
Dividend Yield
N/A
HCA Healthcare stock logo

21. HCA Healthcare NYSE:HCA

$446.58 +6.42 (+1.46%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$447.98 +1.40 (+0.31%)
As of 10/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The company recently reported earnings per share (EPS) of $6.84, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • HCA Healthcare, Inc. has shown a year-over-year revenue increase of 6.4%, suggesting a positive trend in business operations and market demand.
  • The current stock price is around $418, reflecting a robust valuation in the healthcare sector, which may attract investors looking for stable growth opportunities.

Cons of HCA Healthcare

  • HCA Healthcare, Inc. has reported a negative return on equity of over 7,363.11%, which may raise concerns about the company's efficiency in generating profits from shareholders' equity.
  • The company has faced scrutiny regarding its operational practices, which could impact its reputation and long-term sustainability in the competitive healthcare market.
  • Despite recent revenue growth, the healthcare sector is subject to regulatory changes that could adversely affect profitability and operational costs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.99 billion
P/E Ratio
18.77
Consensus Rating
Moderate Buy
Consensus Price Target
$437.19 (-2.1% Downside)
Volume
2.85 million shares
Average Volume
1.24 million shares
Today's Range
$424.00
$461.56
50-Day Range
$393.86
$446.58
52-Week Range
$289.98
$461.56
Dividend Yield
0.65%
CVS Health stock logo

22. CVS Health NYSE:CVS

$81.95 +0.88 (+1.09%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$81.86 -0.09 (-0.12%)
As of 10/24/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $82, reflecting a positive outlook from analysts who have recently upgraded their ratings and price targets for the company.
  • CVS Health Co. has reported strong quarterly earnings, exceeding analysts' expectations with a significant revenue increase, indicating robust business performance.
  • The company offers a competitive dividend yield of 3.2%, providing investors with a steady income stream, which is attractive in the current market environment.

Cons of CVS Health

  • The company's net margin is relatively low at 1.17%, which may indicate challenges in profitability compared to competitors.
  • CVS Health Co. has a dividend payout ratio of 74.30%, suggesting that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Recent analyst downgrades, such as from Zacks Research, indicate some concerns about the stock's performance and future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.82 billion
P/E Ratio
22.89
Consensus Rating
Moderate Buy
Consensus Price Target
$83.38 (+1.7% Upside)
Volume
5.64 million shares
Average Volume
7.17 million shares
Today's Range
$81.09
$82.16
50-Day Range
$70.12
$83.06
52-Week Range
$43.56
$83.52
Dividend Yield
3.28%
McKesson stock logo

23. McKesson NYSE:MCK

$802.17 +9.20 (+1.16%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$803.10 +0.92 (+0.11%)
As of 10/24/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $705, which reflects a strong market capitalization of approximately $98.43 billion, indicating a solid position in the healthcare sector.
  • McKesson Co. recently reported a quarterly revenue of $97.83 billion, surpassing analysts' expectations, showcasing its robust growth and operational efficiency.
  • The company has increased its quarterly dividend to $0.82, representing a positive change from the previous dividend, which may attract income-focused investors.

Cons of McKesson

  • The company reported earnings per share of $8.26, which missed the consensus estimate, indicating potential challenges in meeting market expectations.
  • McKesson Co. has a negative return on equity of 196.66%, suggesting that the company is not generating profit from its equity, which could be a red flag for investors.
  • Insider sales have been significant, with over 24,000 shares sold recently, which may raise concerns about the executives' confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$98.63 billion
P/E Ratio
31.98
Consensus Rating
Moderate Buy
Consensus Price Target
$834.54 (+4.0% Upside)
Volume
476,424 shares
Average Volume
643,295 shares
Today's Range
$791.63
$807.75
50-Day Range
$670.82
$802.17
52-Week Range
$492.39
$807.75
Dividend Yield
0.41%
GSK stock logo

24. GSK NYSE:GSK

$43.24 -2.30 (-5.05%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$43.20 -0.04 (-0.10%)
As of 10/24/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $37.38, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc recently reported strong earnings, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • The company has a solid annualized dividend yield of 3.8%, providing a steady income stream for investors.

Cons of GSK

  • The company has a relatively high dividend payout ratio of 78.24%, which may raise concerns about sustainability if earnings do not grow as expected.
  • Despite recent positive earnings, GSK plc has faced challenges in maintaining consistent revenue growth, which could impact long-term investment returns.
  • Analysts have issued a consensus rating of "Reduce," indicating caution among some market participants regarding the stock's potential upside.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.57 billion
P/E Ratio
20.02
Consensus Rating
Reduce
Consensus Price Target
$37.38 (-13.6% Downside)
Volume
9.86 million shares
Average Volume
6.17 million shares
Today's Range
$42.85
$43.99
50-Day Range
$38.92
$45.52
52-Week Range
$31.72
$46.87
Dividend Yield
3.82%
Bristol Myers Squibb stock logo

25. Bristol Myers Squibb NYSE:BMY

$43.84 +0.01 (+0.03%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$43.76 -0.09 (-0.20%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company reported strong quarterly earnings, with earnings per share (EPS) significantly exceeding consensus estimates, indicating robust financial performance.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and other serious diseases, which can drive future revenue growth.
  • The current stock price is around $70, reflecting a solid position in the market and potential for appreciation as the company continues to innovate.

Cons of Bristol Myers Squibb

  • The company has a high dividend payout ratio of 100%, which may raise concerns about sustainability, especially if earnings fluctuate.
  • Recent revenue growth was only marginal, indicating potential challenges in maintaining momentum in a competitive biopharmaceutical market.
  • There may be uncertainties surrounding the approval and market performance of new drugs, which can impact future earnings and stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$89.21 billion
P/E Ratio
17.68
Consensus Rating
Hold
Consensus Price Target
$57.23 (+30.5% Upside)
Volume
10.10 million shares
Average Volume
17.65 million shares
Today's Range
$43.58
$43.94
50-Day Range
$43.37
$48.38
52-Week Range
$42.96
$63.33
Dividend Yield
5.66%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$301.84 -3.23 (-1.06%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$301.25 -0.59 (-0.20%)
As of 10/24/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $294.79, which may present a buying opportunity for investors looking for value.
  • The Cigna Group has a solid dividend yield of 2.0%, providing a steady income stream for investors.
  • Analysts have a consensus rating of "Moderate Buy" with an average target price of approximately $369.89, indicating potential for price appreciation.

Cons of Cigna Group

  • The stock has experienced a decline of about 2.4% recently, which may indicate short-term volatility and investor uncertainty.
  • Insider selling activity has been noted, with significant shares sold by executives, which could raise concerns about their confidence in the company's future.
  • The stock's price-to-earnings (P/E) ratio of 16.09 may suggest that it is relatively expensive compared to its earnings, potentially limiting upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$81.43 billion
P/E Ratio
16.48
Consensus Rating
Moderate Buy
Consensus Price Target
$369.89 (+22.5% Upside)
Volume
1.32 million shares
Average Volume
1.38 million shares
Today's Range
$300.08
$306.43
50-Day Range
$284.06
$311.24
52-Week Range
$256.89
$350.00
Dividend Yield
1.96%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$342.45 -3.83 (-1.11%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$340.52 -1.94 (-0.57%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$76.96 billion
P/E Ratio
14.00
Consensus Rating
Moderate Buy
Consensus Price Target
$397.89 (+16.2% Upside)
Volume
1.32 million shares
Average Volume
1.93 million shares
Today's Range
$340.04
$349.03
50-Day Range
$306.87
$362.47
52-Week Range
$273.71
$458.75
Dividend Yield
1.98%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$146.14 -0.25 (-0.17%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$146.34 +0.20 (+0.14%)
As of 10/24/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $144, which may present a buying opportunity for investors looking for growth in the animal health sector.
  • Zoetis Inc. reported a strong earnings per share (EPS) of $1.76, exceeding analysts' expectations, indicating robust financial performance and potential for future growth.
  • The company has a high net margin of 27.83%, suggesting efficient management and profitability, which can be attractive to investors seeking stable returns.

Cons of Zoetis

  • The stock has experienced fluctuations, with a 52-week high of $193.49 and a low of $139.34, indicating potential volatility that could concern risk-averse investors.
  • With a price-to-earnings (P/E) ratio of 24.81, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
  • The company has a debt-to-equity ratio of 1.05, suggesting a relatively high level of debt compared to equity, which could pose risks in times of economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$64.88 billion
P/E Ratio
25.15
Consensus Rating
Hold
Consensus Price Target
$195.00 (+33.4% Upside)
Volume
1.38 million shares
Average Volume
2.92 million shares
Today's Range
$145.91
$147.49
50-Day Range
$141.03
$156.69
52-Week Range
$139.34
$184.40
Dividend Yield
1.37%
Cencora stock logo

29. Cencora NYSE:COR

$333.02 +4.46 (+1.36%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$332.10 -0.91 (-0.27%)
As of 10/24/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $319, which reflects a strong market position and investor confidence in the company's growth potential.
  • Recent analyst upgrades have increased price targets, with firms like Wells Fargo raising their target to $354, indicating positive market sentiment.
  • Cencora, Inc. has a solid market capitalization of approximately $61.89 billion, suggesting stability and the ability to invest in growth opportunities.

Cons of Cencora

  • Insider selling has been notable, with significant shares sold recently, which may raise concerns about the executives' confidence in the company's future.
  • The company has a high debt-to-equity ratio of 3.64, indicating that it relies heavily on debt financing, which can be risky in volatile markets.
  • Despite a strong market presence, the stock has experienced fluctuations, with a one-year low of $223.92, suggesting potential volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.70 billion
P/E Ratio
34.26
Consensus Rating
Moderate Buy
Consensus Price Target
$324.91 (-2.4% Downside)
Volume
911,802 shares
Average Volume
1.13 million shares
Today's Range
$327.18
$334.34
50-Day Range
$288.20
$333.02
52-Week Range
$223.92
$334.34
Dividend Yield
0.67%
Regeneron Pharmaceuticals stock logo

30. Regeneron Pharmaceuticals NASDAQ:REGN

$577.95 +2.26 (+0.39%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$576.50 -1.45 (-0.25%)
As of 10/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, reflecting a strong market position and investor confidence in the company's future growth.
  • Regeneron Pharmaceuticals, Inc. reported impressive earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial health.
  • The company has a low debt-to-equity ratio, suggesting a conservative approach to leverage and financial stability, which can be attractive to risk-averse investors.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced fluctuations, with a notable 1-year high and low, indicating potential volatility that could deter risk-averse investors.
  • Despite strong earnings, the company's revenue growth has been modest, which may raise concerns about its ability to sustain long-term growth.
  • Some analysts have issued hold ratings, suggesting that while the stock is stable, there may be limited upside potential in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$61.02 billion
P/E Ratio
14.57
Consensus Rating
Moderate Buy
Consensus Price Target
$802.35 (+38.8% Upside)
Volume
875,215 shares
Average Volume
1.05 million shares
Today's Range
$576.20
$582.70
50-Day Range
$555.51
$600.00
52-Week Range
$476.49
$943.83
Dividend Yield
0.61%
Alnylam Pharmaceuticals stock logo

31. Alnylam Pharmaceuticals NASDAQ:ALNY

$463.43 -0.57 (-0.12%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$466.51 +3.08 (+0.66%)
As of 10/24/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The stock price has recently been set at approximately $456.35, indicating a strong market position and potential for growth.
  • Equities research analysts have shown confidence in the company, with a recent price target increase to $495.00, suggesting an expected upside of over 8% from current levels.
  • Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, reflecting positive sentiment and potential for future performance.

Cons of Alnylam Pharmaceuticals

  • The company has a high debt-to-equity ratio of 4.10, which may indicate financial risk and reliance on debt financing.
  • Alnylam Pharmaceuticals, Inc. has a negative PE ratio of -184.76, suggesting that it is not currently profitable, which can be a concern for potential investors.
  • Despite positive analyst ratings, the stock has experienced volatility, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.82 billion
P/E Ratio
-187.62
Consensus Rating
Moderate Buy
Consensus Price Target
$466.92 (+0.8% Upside)
Volume
771,270 shares
Average Volume
1.05 million shares
Today's Range
$459.38
$469.29
50-Day Range
$443.64
$491.22
52-Week Range
$205.87
$495.55
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$185.85 -0.68 (-0.37%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$185.85 +0.00 (+0.00%)
As of 10/24/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $189, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Recent analyst ratings show a consensus price target of approximately $205.40, indicating potential upside from the current price.
  • Becton, Dickinson and Company has a strong market presence in medical supplies and devices, which are essential for healthcare institutions and have consistent demand.

Cons of Becton, Dickinson and Company

  • The stock has experienced a decline of about 1.1% recently, which may indicate short-term volatility and investor uncertainty.
  • Insider ownership is relatively low at 0.36%, which could suggest a lack of confidence from those closest to the company.
  • The company has a high price-to-earnings (P/E) ratio of 33.99, which may indicate that the stock is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.46 billion
P/E Ratio
33.43
Consensus Rating
Hold
Consensus Price Target
$205.40 (+10.5% Upside)
Volume
1.54 million shares
Average Volume
1.53 million shares
Today's Range
$185.71
$188.52
50-Day Range
$180.86
$199.50
52-Week Range
$163.33
$251.99
Dividend Yield
2.23%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$640.85 +2.25 (+0.35%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$654.11 +13.26 (+2.07%)
As of 10/24/2025 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $633, reflecting a strong performance in the market and indicating investor confidence.
  • IDEXX Laboratories, Inc. reported earnings per share (EPS) of $3.63 for the latest quarter, exceeding analysts' expectations, which demonstrates robust financial health and growth potential.
  • The company has a high return on equity of 64.42%, suggesting effective management and a strong ability to generate profits from shareholders' equity.

Cons of IDEXX Laboratories

  • The stock has a high P/E ratio of 53.03, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been significant, with a total of 54,057 shares sold recently, which could signal a lack of confidence from those closest to the company.
  • The beta of 1.58 suggests that the stock is more volatile than the market, which could lead to larger price swings and increased risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.09 billion
P/E Ratio
53.36
Consensus Rating
Moderate Buy
Consensus Price Target
$656.50 (+2.4% Upside)
Volume
368,179 shares
Average Volume
397,067 shares
Today's Range
$639.08
$650.37
50-Day Range
$616.15
$656.16
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
argenex stock logo

34. argenex NASDAQ:ARGX

$817.32 +5.14 (+0.63%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$816.22 -1.10 (-0.13%)
As of 10/24/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $720, which reflects strong market interest and potential for growth.
  • Recent earnings per share (EPS) of $3.74 exceeded analysts' expectations, indicating robust financial performance.
  • The company reported a significant revenue of $866.79 million, surpassing consensus estimates, showcasing strong sales growth.

Cons of argenex

  • The price-to-earnings (P/E) ratio of 40.87 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • Despite strong performance, the stock has a beta of 0.46, suggesting lower volatility, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Institutional ownership is at 60.32%, which could lead to increased volatility if large investors decide to sell their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.01 billion
P/E Ratio
41.91
Consensus Rating
Moderate Buy
Consensus Price Target
$817.53 (+0.0% Upside)
Volume
198,862 shares
Average Volume
353,176 shares
Today's Range
$809.37
$820.02
50-Day Range
$656.89
$849.46
52-Week Range
$510.05
$855.46
Dividend Yield
N/A
Veeva Systems stock logo

35. Veeva Systems NYSE:VEEV

$293.10 +1.61 (+0.55%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$293.01 -0.10 (-0.03%)
As of 10/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $285.79, which may present a buying opportunity for investors looking for growth in the technology sector.
  • Veeva Systems Inc. reported a revenue increase of 16.7% year-over-year, indicating strong business growth and demand for its cloud-based software solutions in the life sciences industry.
  • The company has a solid net margin of 27.29%, reflecting efficient operations and profitability, which can be attractive to investors seeking stable returns.

Cons of Veeva Systems

  • The company recently missed earnings expectations, reporting an EPS of $1.26 compared to the consensus estimate of $1.90, which may raise concerns about its short-term performance.
  • Insider selling has been notable, with significant shares sold recently, which could signal a lack of confidence among insiders regarding the company's future prospects.
  • The stock has a high P/E ratio of 58.68, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.78 billion
P/E Ratio
60.19
Consensus Rating
Moderate Buy
Consensus Price Target
$307.58 (+4.9% Upside)
Volume
719,787 shares
Average Volume
1.23 million shares
Today's Range
$291.51
$296.55
50-Day Range
$268.85
$306.45
52-Week Range
$201.54
$310.50
Dividend Yield
N/A
Edwards Lifesciences stock logo

36. Edwards Lifesciences NYSE:EW

$76.14 -0.39 (-0.50%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$77.00 +0.86 (+1.12%)
As of 10/24/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The stock has recently shown a positive trend, with a current price around $73.39, indicating potential for growth.
  • Analysts have a consensus rating of "Moderate Buy," suggesting that many believe the stock is undervalued and could appreciate in the future.
  • Several investment firms have recently raised their price targets for Edwards Lifesciences Co., with estimates reaching as high as $94.00, reflecting confidence in the company's future performance.

Cons of Edwards Lifesciences

  • Recent earnings estimates have been lowered by analysts, which may indicate potential challenges in meeting growth expectations.
  • Insider selling activity has been noted, with significant shares sold by executives, which could signal a lack of confidence in the company's short-term prospects.
  • The stock has experienced fluctuations, with a one-year high of $83.00 and a low of $64.89, suggesting volatility that may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.93 billion
P/E Ratio
10.96
Consensus Rating
Moderate Buy
Consensus Price Target
$87.06 (+14.3% Upside)
Volume
3.17 million shares
Average Volume
4.12 million shares
Today's Range
$76.09
$77.16
50-Day Range
$72.66
$81.76
52-Week Range
$64.89
$83.00
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

37. Takeda Pharmaceutical NYSE:TAK

$14.02 -0.04 (-0.25%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$14.01 -0.02 (-0.11%)
As of 10/24/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The company recently reported earnings per share that exceeded analyst expectations, indicating strong financial performance and potential for growth.
  • Takeda Pharmaceutical Company Limited has a solid return on equity, suggesting effective management and profitability in generating returns for shareholders.
  • The current stock price is around $13.72, which may present a buying opportunity for investors looking for value in the healthcare sector.

Cons of Takeda Pharmaceutical

  • The company reported revenue that fell short of analyst expectations, which may raise concerns about its ability to meet future growth targets.
  • Takeda Pharmaceutical Company Limited has a relatively low net margin, suggesting that profitability could be a concern in a competitive market.
  • Recent downgrades from analysts, including a shift from "hold" to "strong sell," may indicate potential risks associated with the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.74 billion
P/E Ratio
46.75
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
1.47 million shares
Average Volume
2.72 million shares
Today's Range
$13.99
$14.06
50-Day Range
$13.72
$15.50
52-Week Range
$12.80
$15.69
Dividend Yield
3.93%
Agilent Technologies stock logo

38. Agilent Technologies NYSE:A

$148.03 +0.57 (+0.39%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$148.03 0.00 (0.00%)
As of 10/24/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $145, reflecting a strong market position and investor confidence in the company's growth potential.
  • Agilent Technologies, Inc. reported a revenue increase of over 10% year-over-year, indicating robust demand for its products and services in the medical research sector.
  • The company has a solid return on equity of 25.51%, showcasing its efficiency in generating profits from shareholders' equity.

Cons of Agilent Technologies

  • The company has a relatively high price-to-earnings (P/E) ratio of 34.22, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • Despite recent revenue growth, the competitive landscape in the medical research industry could pose challenges, as new entrants may impact market share and pricing power.
  • Agilent Technologies, Inc. has a beta of 1.26, indicating that its stock price is more volatile than the market, which could lead to higher risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.80 billion
P/E Ratio
34.75
Consensus Rating
Moderate Buy
Consensus Price Target
$149.62 (+1.1% Upside)
Volume
1.14 million shares
Average Volume
1.79 million shares
Today's Range
$147.52
$149.12
50-Day Range
$117.08
$148.03
52-Week Range
$96.43
$153.84
Dividend Yield
0.67%
Haleon stock logo

39. Haleon NYSE:HLN

$9.24 -0.13 (-1.33%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$9.22 -0.03 (-0.32%)
As of 10/24/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $8.94, which may present a buying opportunity for investors looking for potential growth.
  • Haleon plc has recently increased its semi-annual dividend to $0.0555 per share, reflecting a commitment to returning value to shareholders.
  • The company has a market capitalization of approximately $39.81 billion, indicating a strong presence in the consumer healthcare sector.

Cons of Haleon

  • The stock has a PE ratio of 22.91, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent analyst downgrades, including a shift from "overweight" to "equal weight," may signal concerns about the company's growth prospects.
  • The current ratio of 0.87 suggests that Haleon plc may have difficulty meeting its short-term liabilities, which could pose a risk in times of financial strain.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.73 billion
P/E Ratio
23.71
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+33.3% Upside)
Volume
8.98 million shares
Average Volume
9.21 million shares
Today's Range
$9.24
$9.35
50-Day Range
$8.74
$9.91
52-Week Range
$8.71
$11.42
Dividend Yield
1.21%
ResMed stock logo

40. ResMed NYSE:RMD

$259.87 -5.39 (-2.03%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$259.50 -0.38 (-0.15%)
As of 10/24/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The company reported earnings per share of $2.55 for the latest quarter, exceeding expectations, which indicates strong financial performance and potential for growth.
  • ResMed Inc. has increased its quarterly dividend to $0.60 per share, reflecting a commitment to returning value to shareholders, with an annualized dividend yield of approximately 0.9%.
  • Recent revenue growth of over 10% year-over-year suggests that ResMed Inc. is expanding its market presence and demand for its medical equipment and software solutions.

Cons of ResMed

  • Insider selling activity has been noted, with significant shares sold by executives, which could raise concerns about their confidence in the company's future performance.
  • The stock has seen fluctuations, and while it has performed well recently, market volatility could impact future stock performance.
  • Despite positive earnings, the dividend yield of 0.9% is relatively low compared to other investment opportunities, which may not attract income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.71 billion
P/E Ratio
27.33
Consensus Rating
Moderate Buy
Consensus Price Target
$295.70 (+13.8% Upside)
Volume
1.11 million shares
Average Volume
921,968 shares
Today's Range
$259.41
$266.97
50-Day Range
$259.87
$293.48
52-Week Range
$199.92
$293.81
Dividend Yield
0.90%
Cardinal Health stock logo

41. Cardinal Health NYSE:CAH

$161.82 +2.67 (+1.67%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$161.52 -0.31 (-0.19%)
As of 10/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $151, which is significantly higher than its 1-year low of $106.98, indicating a potential for growth.
  • Cardinal Health, Inc. recently reported earnings that exceeded analyst expectations, showcasing its ability to perform well in a competitive market.
  • The company has a solid market capitalization of approximately $36.61 billion, reflecting its stability and presence in the healthcare sector.

Cons of Cardinal Health

  • The company has a negative return on equity of 74.45%, which may indicate inefficiencies in generating profit from shareholders' equity.
  • Despite a slight increase in revenue, it fell short of analyst expectations, which could raise concerns about future performance.
  • The net margin of 0.70% is relatively low, suggesting that the company may not be effectively converting sales into profit.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.81 billion
P/E Ratio
25.09
Consensus Rating
Moderate Buy
Consensus Price Target
$166.00 (+2.6% Upside)
Volume
1.82 million shares
Average Volume
2.23 million shares
Today's Range
$158.70
$162.19
50-Day Range
$146.18
$161.83
52-Week Range
$106.98
$168.44
Dividend Yield
1.28%
Alcon stock logo

42. Alcon NYSE:ALC

$76.13 -0.13 (-0.17%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$76.47 +0.34 (+0.45%)
As of 10/24/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is approximately $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that may attract investors.
  • Institutional ownership is relatively high, suggesting confidence from large investors in the company's future prospects.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which could indicate reduced investor interest.
  • The month-to-month change in shares shorted has shown a significant decline, which may suggest volatility in investor confidence.
  • With a relatively low short percentage of float, there may be limited potential for short covering rallies that can drive prices higher.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.61 billion
P/E Ratio
35.41
Consensus Rating
Moderate Buy
Consensus Price Target
$91.50 (+20.2% Upside)
Volume
1.36 million shares
Average Volume
2.34 million shares
Today's Range
$76.08
$77.01
50-Day Range
$71.99
$90.14
52-Week Range
$71.55
$99.20
Dividend Yield
N/A
IQVIA stock logo

43. IQVIA NYSE:IQV

$220.64 +0.73 (+0.33%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$219.80 -0.85 (-0.38%)
As of 10/24/2025 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The company recently reported earnings per share (EPS) of $2.81, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • IQVIA Holdings Inc. has shown a revenue increase of 5.3% compared to the same quarter last year, reflecting its ability to grow in a competitive market.
  • The current stock price is around $212, which is near its 52-week high, suggesting strong market confidence in the company's future prospects.

Cons of IQVIA

  • Insider selling has been observed, with key executives reducing their holdings, which may signal a lack of confidence in the company's short-term performance.
  • The company's debt-to-equity ratio is relatively high at 2.45, indicating that it relies heavily on debt financing, which could pose risks in a rising interest rate environment.
  • Despite recent revenue growth, the net margin of 7.88% suggests that profitability may be under pressure, which could affect future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.38 billion
P/E Ratio
31.93
Consensus Rating
Moderate Buy
Consensus Price Target
$234.57 (+6.3% Upside)
Volume
1.29 million shares
Average Volume
1.63 million shares
Today's Range
$219.92
$221.97
50-Day Range
$176.72
$220.64
52-Week Range
$134.65
$225.91
Dividend Yield
N/A
GE HealthCare Technologies stock logo

44. GE HealthCare Technologies NASDAQ:GEHC

$78.14 +0.88 (+1.14%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$78.00 -0.14 (-0.19%)
As of 10/24/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported earnings that exceeded expectations, with an EPS of $1.06, indicating strong financial performance and effective management.
  • GE HealthCare Technologies Inc. has a solid return on equity of nearly 24%, suggesting efficient use of shareholder funds to generate profits.
  • The current stock price is around $72.86, which is relatively stable compared to its one-year high of $94.80, indicating potential for recovery and growth.

Cons of GE HealthCare Technologies

  • Despite recent earnings growth, the stock has experienced volatility, with a one-year low of $57.65, indicating potential risks in price stability.
  • Some analysts have downgraded their ratings, reflecting concerns about market conditions and competitive pressures in the healthcare technology sector.
  • The company has a debt-to-equity ratio of 0.85, which, while manageable, suggests that it relies on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.27 billion
P/E Ratio
16.01
Consensus Rating
Moderate Buy
Consensus Price Target
$85.20 (+9.0% Upside)
Volume
2.60 million shares
Average Volume
2.77 million shares
Today's Range
$77.14
$78.33
50-Day Range
$71.01
$78.71
52-Week Range
$57.65
$94.80
Dividend Yield
0.18%
Humana stock logo

45. Humana NYSE:HUM

$290.65 -0.65 (-0.22%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$293.05 +2.40 (+0.82%)
As of 10/24/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $298, reflecting a stable position in the market.
  • Humana Inc. reported a significant revenue increase of 9.6% compared to the same quarter last year, indicating strong business growth.
  • The company has a solid return on equity of 13.67%, showcasing effective management and profitability.

Cons of Humana

  • The stock has received a "sell" rating from Weiss Ratings, which may indicate potential risks in the investment.
  • Some analysts have significantly lowered their price targets, suggesting a lack of confidence in short-term performance.
  • Humana Inc. reported earnings per share that missed analysts' expectations, which could raise concerns about its profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.04 billion
P/E Ratio
22.31
Consensus Rating
Hold
Consensus Price Target
$297.58 (+2.4% Upside)
Volume
791,906 shares
Average Volume
1.98 million shares
Today's Range
$287.65
$292.00
50-Day Range
$246.89
$312.22
52-Week Range
$206.87
$315.35
Dividend Yield
1.23%
BeOne Medicines stock logo

46. BeOne Medicines NASDAQ:ONC

$310.81 +0.78 (+0.25%)
As of 10/24/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$33.98 billion
P/E Ratio
-179.66
Consensus Rating
Moderate Buy
Consensus Price Target
$345.60 (+11.2% Upside)
Volume
112,628 shares
Average Volume
231,781 shares
Today's Range
$309.00
$314.95
50-Day Range
$297.96
$351.13
52-Week Range
$170.99
$355.30
Dividend Yield
N/A
Insmed stock logo

47. Insmed NASDAQ:INSM

$159.66 -0.46 (-0.29%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$159.25 -0.41 (-0.26%)
As of 10/24/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$33.85 billion
P/E Ratio
-27.96
Consensus Rating
Moderate Buy
Consensus Price Target
$152.88 (-4.2% Downside)
Volume
1.11 million shares
Average Volume
1.96 million shares
Today's Range
$158.81
$162.29
50-Day Range
$127.21
$167.91
52-Week Range
$60.40
$168.21
Dividend Yield
N/A
Mettler-Toledo International stock logo

48. Mettler-Toledo International NYSE:MTD

$1,435.51 -2.24 (-0.16%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$1,430.82 -4.69 (-0.33%)
As of 10/24/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.

Market Capitalization
$29.62 billion
P/E Ratio
36.35
Consensus Rating
Hold
Consensus Price Target
$1,336.50 (-6.9% Downside)
Volume
135,091 shares
Average Volume
142,915 shares
Today's Range
$1,421.98
$1,454.68
50-Day Range
$1,191.70
$1,436.21
52-Week Range
$946.69
$1,454.68
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$28.88 -0.14 (-0.47%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$28.94 +0.06 (+0.21%)
As of 10/24/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $26.81, which may present a buying opportunity for investors looking for value in the technology sector.
  • Recent institutional investments, such as Ballentine Partners LLC increasing its stake by 138.2%, indicate strong confidence in the company's future performance.
  • Koninklijke Philips reported a significant revenue of $5.05 billion in its latest earnings, surpassing analysts' expectations, which reflects robust operational performance.

Cons of Koninklijke Philips

  • The stock has a high P/E ratio of 141.11, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite recent revenue growth, the company has a net margin of only 1.00%, indicating that profitability may be a concern for long-term investors.
  • Recent analyst downgrades, such as Wall Street Zen reducing its rating from "buy" to "hold," may signal caution regarding the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.93 billion
P/E Ratio
151.97
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
474,697 shares
Average Volume
541,849 shares
Today's Range
$28.83
$29.02
50-Day Range
$26.58
$29.03
52-Week Range
$21.48
$32.08
Dividend Yield
2.83%
DexCom stock logo

50. DexCom NASDAQ:DXCM

$70.33 -0.73 (-1.03%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$70.55 +0.22 (+0.31%)
As of 10/24/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Market Capitalization
$27.87 billion
P/E Ratio
48.84
Consensus Rating
Moderate Buy
Consensus Price Target
$97.19 (+38.2% Upside)
Volume
3.16 million shares
Average Volume
4.63 million shares
Today's Range
$70.31
$72.08
50-Day Range
$65.12
$82.26
52-Week Range
$57.52
$93.25
Dividend Yield
N/A